Document ID: chunk:federal_register_of_legislation:F2025C00036:reg:6
Version: federal_register_of_legislation:F2025C00036
Segment Type: reg
Provision Reference: reg 6
Character Range: 217768–220314

6                            (a) cannabidiol derived from cannabis comprises 40% or more and less than 60% of the total cannabinoid content of the medicine; and                                                     capsule      oral                     treatment of refractory chronic pain in adult patients
                             (b) other cannabinoids (including tetrahydrocannabinol) derived from cannabis comprise the remaining cannabinoid content of the medicine; and
                             (c) the medicine contains no other active ingredients

 (2) The class of recipients prescribed for the purposes of paragraph 19(6)(b) of the Act is the class of recipients consisting of persons each of whom is suffering from a life‑threatening, or otherwise serious, illness or condition.
 (3) For the purposes of subsection 19(7) of the Act, the prescribed circumstances in which a medicine, or a class of medicines, may be supplied in accordance with an authority under subsection 19(5) of the Act are that the supplier of the medicine or class of medicines complies with the treatment directions (if any) mentioned in the authority for the medicine or class of medicine.
 (5) For the purposes of paragraph 19(7B)(b) of the Act, rules made under subsection 19(7A) of the Act must not specify a medicine or a class of medicines if the medicine, or a medicine included in the class, contains a substance of a kind covered by an entry in Schedule 8, 9 or 10 to the Poisons Standard.
 (6) For the purposes of paragraph 19(7D)(b) of the Act, the information that must be contained in a notification under subsection 19(7C) of the Act in relation to the supply by a health practitioner of a medicine to a person is as follows:
 (a) the person's initials, date of birth and gender;
 (b) each medical condition in relation to which the medicine was supplied;
 (c) each indication of the medicine in relation to which the medicine was supplied;
 (d) each active ingredient of the medicine;
 (e) the dosage form of the medicine;
 (f) if the release mechanism of the medicine was clinically relevant to the supply of the medicine—information about the release mechanism;
 (g) if the route of administration of the medicine was clinically relevant to the supply of the medicine—information about the route of administration;
 (h) the practitioner's name, AHPRA number and contact details;
 (i) the health profession in which the practitioner is registered or licensed to practise;
 (j) the address of the practitioner's principal place of practice.